|
AMG 193 Clinical Trials
3 actively recruiting trials across 2 locations
Pipeline
Phase 1: 2Phase 2: 1
Top Sponsors
- Amgen3
Indications
- Cancer3
- Lung Cancer2
- Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers1
- MTAP-deleted NSCLC1
- Thoracic Tumors1
Bakersfield, California2 trials
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
Comprehensive Blood and Cancer Center
Phase 1
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Comprehensive Blood and Cancer Center
Phase 1
Duarte, California1 trial
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
City of Hope National Medical Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.